476 related articles for article (PubMed ID: 22578732)
1. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.
Abdollah F; Schmitges J; Sun M; Jeldres C; Tian Z; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Int J Urol; 2012 Sep; 19(9):836-44. PubMed ID: 22574746
[TBL] [Abstract][Full Text] [Related]
3. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
[TBL] [Abstract][Full Text] [Related]
4. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
[TBL] [Abstract][Full Text] [Related]
5. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
6. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
Arvold ND; Chen MH; Moul JW; Moran BJ; Dosoretz DE; Bañez LL; Katin MJ; Braccioforte MH; D'Amico AV
J Urol; 2011 Jul; 186(1):91-6. PubMed ID: 21571341
[TBL] [Abstract][Full Text] [Related]
7. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
9. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
[TBL] [Abstract][Full Text] [Related]
10. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
11. Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy.
Froehner M; Koch R; Litz RJ; Oehlschlaeger S; Twelker L; Hakenberg OW; Wirth MP
Urology; 2008 Dec; 72(6):1252-7. PubMed ID: 18723211
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
[TBL] [Abstract][Full Text] [Related]
13. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach.
Tewari A; Divine G; Chang P; Shemtov MM; Milowsky M; Nanus D; Menon M
J Urol; 2007 Mar; 177(3):911-5. PubMed ID: 17296374
[TBL] [Abstract][Full Text] [Related]
16. Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria.
Gandaglia G; Karakiewicz PI; Briganti A; Trudeau V; Trinh QD; Kim SP; Montorsi F; Nguyen PL; Abdollah F; Sun M
Int J Urol; 2015 Jan; 22(1):89-95. PubMed ID: 25141965
[TBL] [Abstract][Full Text] [Related]
17. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity.
Alibhai SM; Leach M; Tomlinson G; Krahn MD; Fleshner N; Holowaty E; Naglie G
J Natl Cancer Inst; 2005 Oct; 97(20):1525-32. PubMed ID: 16234566
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).
Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M
Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648
[TBL] [Abstract][Full Text] [Related]
19. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
20. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer.
Linder BJ; Boorjian SA; Umbreit EC; Carlson RE; Rangel LJ; Bergstralh EJ; Karnes RJ
Int J Urol; 2013 Aug; 20(8):798-805. PubMed ID: 23278850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
